Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Payables: 2021-2024

Historic Payables for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $2.0 million.

  • Kiniksa Pharmaceuticals International's Payables fell 26.15% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 35.38%. This contributed to the annual value of $2.0 million for FY2024, which is 75.27% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Payables stood at $2.0 million for FY2024, which was down 75.27% from $8.2 million recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Payables peaked at $8.2 million during FY2023, and registered a low of $1.9 million during FY2021.
  • Moreover, its 3-year median value for Payables was $7.9 million (2022), whereas its average is $6.1 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Payables spiked by 322.86% in 2022 and then plummeted by 75.27% in 2024.
  • Kiniksa Pharmaceuticals International's Payables (Yearly) stood at $1.9 million in 2021, then surged by 322.86% to $7.9 million in 2022, then climbed by 4.39% to $8.2 million in 2023, then plummeted by 75.27% to $2.0 million in 2024.